| 1.16 -0.28 (-19.44%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.81 |
1-year : | 2.13 |
| Resists | First : | 1.55 |
Second : | 1.83 |
| Pivot price | 1.4 |
|||
| Supports | First : | 1.1 |
Second : | 0.91 |
| MAs | MA(5) : | 1.47 |
MA(20) : | 1.34  |
| MA(100) : | 1.34 |
MA(250) : | 0.99 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 35.8 |
D(3) : | 54.7 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 1.83 | Low : | 0.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LXRX ] has closed above bottom band by 19.5%. Bollinger Bands are 167.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.3 - 1.31 | 1.31 - 1.32 |
| Low: | 1.09 - 1.1 | 1.1 - 1.1 |
| Close: | 1.15 - 1.16 | 1.16 - 1.17 |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Fri, 30 Jan 2026
Citi Raises Lexicon Pharmaceuticals (LXRX) Outlook on Strength of Novo Nordisk Partnership Milestones - Yahoo Finance
Fri, 30 Jan 2026
Lexicon Pharmaceuticals (LXRX) Engages Jefferies and Piper Sandl - GuruFocus
Fri, 30 Jan 2026
Lexicon Pharmaceuticals (LXRX) Raises $41.6M Through Public Offe - GuruFocus
Fri, 30 Jan 2026
Lexicon Pharmaceuticals prices public offering at $1.30 per share - Investing.com
Fri, 30 Jan 2026
Lexicon Pharmaceuticals Announces Pricing of $41.6 Million Public Offering of Common Stock - Quiver Quantitative
Fri, 30 Jan 2026
Drug developer Lexicon raises $94.6M to fund pipeline and operations - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 363 (M) |
| Shares Float | 184 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 71.8 (%) |
| Shares Short | 23,660 (K) |
| Shares Short P.Month | 24,230 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.33 |
| Profit Margin | -96.8 % |
| Operating Margin | -86 % |
| Return on Assets (ttm) | -13 % |
| Return on Equity (ttm) | -46 % |
| Qtrly Rev. Growth | 710.4 % |
| Gross Profit (p.s.) | -0.02 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -0.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -72 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -6.11 |
| PEG Ratio | 0 |
| Price to Book value | 3.51 |
| Price to Sales | 5.94 |
| Price to Cash Flow | -5.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |